Cephalon Fentora sNDA In Non-Cancer Pain Slated For Fourth Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm is analyzing Phase III data to determine the specific claim to pursue.
You may also be interested in...
Cephalon Revises Fentora Labeling To Highlight Patient Selection Criteria Following Deaths
Among the deaths associated with the breakthrough cancer pain treatment were two patients prescribed the drug for migraines, Cephalon tells “The Pink Sheet” DAILY.
Cephalon Revises Fentora Labeling To Highlight Patient Selection Criteria Following Deaths
Among the deaths associated with the breakthrough cancer pain treatment were two patients prescribed the drug for migraines, Cephalon tells “The Pink Sheet” DAILY.
Cephalon Adds Amrix To Pain Portfolio From ECR Pharmaceuticals Deal
Company plans to launch the drug in the fourth quarter using its pain and CNS sales forces, CEO Baldino tells “The Pink Sheet” DAILY.